T-Cell Prolymphocytic Leukemia — Trials

T-Cell Prolymphocytic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 8
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 25%
Top sponsor: Ascentage Pharma Group Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07311746	Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia	recruiting	Phase 1 / Phase 2	36	M.D. Anderson Cancer CenterOTHER	1	Aug 12, 2026	clinicaltrials
NCT06810778	Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	recruiting	Phase 1 / Phase 2	12	Jonsson Comprehensive Cancer CenterOTHER	1	Jul 17, 2026	clinicaltrials